MedPath

Filter Lenses for the Prevention of Migraine Attacks

Not Applicable
Not yet recruiting
Conditions
Glasses
Headache
Migraine
Visual Impairment
Interventions
Device: Lenses
Registration Number
NCT06161129
Lead Sponsor
Rune Skovgaard Rasmussen
Brief Summary

The purpose is to investigate whether the Blue Cut for Night filter is better at reducing migraine compared to the FL-41 filter or a filter blocking light below 500 nm. A control group will use clear lenses without filter. This is a controlled, randomized and double-blind trial.

Detailed Description

Migraine is a neurological disorder that often causes severe, throbbing headaches that can be accompanied by nausea and vomiting. In addition, sound or light sensitivity is often seen. An attack can last up to 72 hours. Migraine can occur in one half of the head and is exacerbated by physical activity. There are several different types of migraine, of which the inherited migraine typically cannot be cured. Migraine affects about 15% of all adults worldwide, but about twice as many women as men.

About 10% of diagnosed patients have chronic migraine, which is characterized by at least 15 days of severe headache each month. Many patients have tension headaches between attacks.

Migraine most often starts in the most productive years of life, between the ages of 20 and 50, and most affects the age group of 35-54 years. For many women, migraine debuts after childbirth, while others experience that it disappears after childbirth. Several women experience that they get migraine when they have their period. This migraine is called hormonal and can follow them for many years.

Several studies have shown that migraine attacks are triggered by light, and many become very light-sensitive during an attack. So far, a FL 41 lens, which excludes blue-green light, has been the only migraine-specific optical treatment.

A new lens called "Blue Cut for Night Glass" has in a study resulted in participants experiencing less migraine. For 4 weeks, 10 participants used only the lens in the evening. Results showed that they had fewer days with headaches. The lens is so new that it has not yet come into regular production and trade. In connection with the present study, the investigators have received 13 sets of lenses.

For many years, FL-41 has been the preferred filter lens for the prevention of migraine attacks, since it was first successfully tested on children in 1991. Since this study, much has happened in terms of the development of filter lenses.

The purpose is to investigate whether the Blue Cut for Night filter is better at reducing migraine compared to the FL-41 filter or a filter blocking light below 500 nm. A control group will use clear lenses without filter. This is a controlled, randomized and double-blind trial.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
200
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
BlueCutLensesGroup of 50 participants will receive glasses with a Blue Cut filter.
500nmLensesGroup of 50 participants will receive glasses with a below 500 nm filter
FL-41LensesGroup of 50 participants will receive a glasses with an FL-41 filter.
Primary Outcome Measures
NameTimeMethod
Change of pain intensity during migraine attacksMeasured at inclusion, 4 weeks after inclusion, and 8 weeks after inclusion

Intensity is described from 1-10 on a visual analog pain scale (VAS). A score of 1 is very mild intensity and 10 is very severe.

Secondary Outcome Measures
NameTimeMethod
Fatigue Severity ScaleMeasured at inclusion, 4 weeks after inclusion, and 8 weeks after inclusion

Short fatigue questionnaire used to assess the occurrence of disabling fatigue. There are 9 items scored from 1 to 7, where 7 indicated the most fatigue. A score of 63 is worst, and disabling fatigue may be observed scoring 45 or more points.

Medication use, both as needed (PN) and daily fixed medicationEvery day of participation lasting 8 weeks

Consumption of preparations and dosage is recorded in a diary

Major Depression InventoryMeasured at inclusion, 4 weeks after inclusion, and 8 weeks after inclusion

About 80% of people with chronic migraine are affected by depression. Major Depression Inventory is used in the present study to monitor for symptoms of depression as well as part of the assessment of mental well-being and quality of life

The 36-Item Health SurveyMeasured at inclusion, 4 weeks after inclusion, and 8 weeks after inclusion

The 36-Item Health Survey is used to measure quality of life and is frequently used to measure the effectiveness of different treatments for headache-affected persons. The questionnaire has 8 dimensions ranging for 0 to 100 points, where a high score indicates better functioning. The 8 dimensions are: physical functioning, role physical, bodily pain, general health perceptions, vitality, social function, role emotional, og mental health.

Assessment of photophobia via questionnaireMeasured at inclusion, 4 weeks after inclusion, and 8 weeks after inclusion

Assessment of photophobia via questionnaire, where each participant assesses their own light sensitivity during the day, at night, and indoors. This is done both with and without filter glasses. The amount of photophobia is measured on a scale from 0 to 10, where 10 indicates maximum and worst photophobia.

Headache Impact Test (HIT-6)Measured at inclusion, 4 weeks after inclusion, and 8 weeks after inclusion

Headache Impact Test (HIT-6), which is a validated questionnaire. It consists of 6 questions and assesses participants' functional status in the past 4 weeks. The questions measure the frequency and severity of headaches, as well as their consequences for the participant's activity level. The scale scores from 36 to 78, with a high score being the worst. This questionnaire is recommended by the Danish Medicines Council for Danish migraine patients

Migraine-Specific Quality-of-Life Questionnaire v. 2.1 (MSQ)Measured at inclusion, 4 weeks after inclusion, and 8 weeks after inclusion

MSQ is a frequently used disease-specific survey for assessing health-related quality of life in people with migraine. MSQ is validated for persons with episodic migraine and persons with chronic migraine. MSQ measures quality of life within the last 4 weeks in relation to restrictive function, preventive function, and emotional function. The score ranges from 0-100, with a higher score indicating improvement in quality of life

Monthly migraine daysEvery day of participation lasting 8 weeks

The date of the migraine attack, duration, and medication used are noted. A migraine day is defined as a day on which the person experienced a migraine attack or used medication to relieve acute attacks

Groffman Visual Tracing TestMeasured at inclusion, 4 weeks after inclusion, and 8 weeks after inclusion

Test for assessment of attention, visuospatial function, and figure-ground perception. The test is stressful and requires a high degree of sustained visual focus, and can be expected to be affected by pain, fatigue, light sensitivity, and oculomotor dysfunction

The Migraine Disability Assessment TestMeasured at inclusion, 4 weeks after inclusion, and 8 weeks after inclusion

The questionnaire is changed to a 1-month focus period instead of 3 months. The Migraine Disability Assessment Test is frequently used to measure the effectiveness of interventions for migraine

Trial Locations

Locations (1)

CSU-Slagelse

🇩🇰

Slagelse, Denmark

CSU-Slagelse
🇩🇰Slagelse, Denmark
Peter Smaakjær, MSc
Contact
58575769
pesma@slagelse.dk
Rune S Rasmussen
Contact
28757500
rsras@slagelse.dk
© Copyright 2025. All Rights Reserved by MedPath